CN1523987A - 治疗牙周疾病的免疫反应调节剂 - Google Patents

治疗牙周疾病的免疫反应调节剂 Download PDF

Info

Publication number
CN1523987A
CN1523987A CNA028118715A CN02811871A CN1523987A CN 1523987 A CN1523987 A CN 1523987A CN A028118715 A CNA028118715 A CN A028118715A CN 02811871 A CN02811871 A CN 02811871A CN 1523987 A CN1523987 A CN 1523987A
Authority
CN
China
Prior art keywords
alkyl
use according
immune response
carbon atoms
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028118715A
Other languages
English (en)
Chinese (zh)
Inventor
苏米塔・B・米特拉
苏米塔·B·米特拉
・E・塞尔伯恩
查尔斯·E·塞尔伯恩
A・托迈
马克·A·托迈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of CN1523987A publication Critical patent/CN1523987A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CNA028118715A 2001-06-15 2002-06-14 治疗牙周疾病的免疫反应调节剂 Pending CN1523987A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29876801P 2001-06-15 2001-06-15
US60/298,768 2001-06-15

Publications (1)

Publication Number Publication Date
CN1523987A true CN1523987A (zh) 2004-08-25

Family

ID=23151928

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028118715A Pending CN1523987A (zh) 2001-06-15 2002-06-14 治疗牙周疾病的免疫反应调节剂

Country Status (5)

Country Link
EP (1) EP1401437A1 (enExample)
JP (1) JP2005519849A (enExample)
CN (1) CN1523987A (enExample)
CA (1) CA2449754A1 (enExample)
WO (1) WO2002102377A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114616234A (zh) * 2019-02-07 2022-06-10 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
CA2467828C (en) 2001-11-29 2011-10-04 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
WO2004080430A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Methods of improving skin quality
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
PT1478327E (pt) 2002-02-22 2015-08-04 Meda Ab Método de redução e tratamento de imunossupressão induzida por uvb
JP2005538057A (ja) 2002-06-07 2005-12-15 スリーエム イノベイティブ プロパティズ カンパニー エーテル置換イミダゾピリジン
US7427629B2 (en) 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (ja) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
EP1590348A1 (en) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
EP1601365A4 (en) 2003-03-04 2009-11-11 3M Innovative Properties Co PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
AU2004244962A1 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
JP2007503268A (ja) 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
NZ545412A (en) 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
WO2005020995A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
JP2007513165A (ja) * 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物を含む併用薬および治療方法
JP2008530022A (ja) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫反応調節物質を含む水性ゲル処方物
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
EP2378876B1 (en) 2008-12-19 2018-11-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
MX336923B (es) 2009-07-13 2016-02-05 Medicis Pharmaceutical Corp Formulaciones de imiquimod de concentracion de dosificacion inferior y regimenes de dosificacion cortos para tratar verrugas genitales y perianales.
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
JPWO2019216438A1 (ja) * 2018-05-11 2021-05-20 株式会社ジーンテクノサイエンス 間葉系細胞の培養上清を含む歯周病治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420168D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
JP2004504389A (ja) * 2000-07-13 2004-02-12 アルテオン　インコーポレーテッド シアノメチル置換化チアゾリウム及びイミダゾリウム、並びにタンパク質老化と関連する疾患の治療

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114616234A (zh) * 2019-02-07 2022-06-10 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
CN114616234B (zh) * 2019-02-07 2024-04-12 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用

Also Published As

Publication number Publication date
JP2005519849A (ja) 2005-07-07
WO2002102377A1 (en) 2002-12-27
EP1401437A1 (en) 2004-03-31
CA2449754A1 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
CN1103219C (zh) 含有透明质酸的制剂
CN1235559C (zh) 皮肤水分保持能力的改善剂
US7226928B2 (en) Methods for the treatment of periodontal disease
CN100346788C (zh) 用于鼻内给药的芬太尼组合物
JP2005519849A (ja) 歯周病の治療用免疫応答調節剤
CN1212841C (zh) 减轻阿扑吗啡的副作用
US20030130299A1 (en) Method for the treatment of periodontal disease
CN1248734C (zh) 用于伤口愈合的基质蛋白组合物
CN1148187C (zh) 粉防己碱或其激动剂在制备治疗眼炎的药物中的应用
CN1196473C (zh) 油性佐剂疫苗及其制备方法
CN1555264A (zh) 用于治疗粘膜病症的含咪喹莫特或其它免疫应答调节剂的制剂
CN1610550A (zh) 包括免疫反应改性剂的药物制剂
CN1882353A (zh) 催涎剂和混合该催涎剂的口腔用组合物以及食品组合物
CN1044047A (zh) 抗蚀斑抗菌口用复方
CN1561389A (zh) 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
CN1515258A (zh) 骨质疏松症的联合疗法
CN1946392A (zh) 含有单乙酰基二酰基甘油衍生物的免疫调节剂、抗癌剂和健康食品
CN1826127A (zh) 用于促进热休克蛋白合成的一种含有以富含羽扇醇的提取物为活性成分的化妆品或药学组合物的用途
Gonçalves et al. MMP13, TIMP2 and TGFB3 gene polymorphisms in Brazilian chronic periodontitis and periimplantitis subjects
CN1674930A (zh) 包含组合物的酶,所述组合物的生产工艺及其用途
CN1708312A (zh) 新的天然来源的葡萄糖苷酶抑制剂
CN1620301A (zh) 医药上可接受的带有磷酸盐－甘油的主体
CN1735431A (zh) 作为免疫调节物的全细菌细胞
Cury et al. Evaluation of the effect of tumor necrosis factor-alpha gene polymorphism on the risk of peri-implantitis: a case-control study.
CN1525858A (zh) 包括调节胆碱能功能的烟碱性受体部分拮抗剂与止吐药的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication